Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-11-27

FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for COMPLERA (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate) submitted by Gilead Scien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COMPLERA (Emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)

Snippet

SUPPL AP for COMPLERA (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE)